Increased RUNX1 mutations in breast cancer disease progression

Despite advances in screening, therapy and surveillance, breast cancer remains threatening to women. Worst, patients suffer from side effects of treatments and cancer cells become resistant. The emergence of RUNX1 in breast cancer has put it in a spotlight due to its roles in the disease progression...

Full description

Bibliographic Details
Published in:PATHOLOGY RESEARCH AND PRACTICE
Main Authors: Ariffin, Nur Syamimi
Format: Article
Language:English
Published: ELSEVIER GMBH 2024
Subjects:
Online Access:https://www-webofscience-com.uitm.idm.oclc.org/wos/woscc/full-record/WOS:001164317100001
author Ariffin
Nur Syamimi
spellingShingle Ariffin
Nur Syamimi
Increased RUNX1 mutations in breast cancer disease progression
Pathology
author_facet Ariffin
Nur Syamimi
author_sort Ariffin
spelling Ariffin, Nur Syamimi
Increased RUNX1 mutations in breast cancer disease progression
PATHOLOGY RESEARCH AND PRACTICE
English
Article
Despite advances in screening, therapy and surveillance, breast cancer remains threatening to women. Worst, patients suffer from side effects of treatments and cancer cells become resistant. The emergence of RUNX1 in breast cancer has put it in a spotlight due to its roles in the disease progression. It also plays important roles in normal mammary glands such as for cell growth, proliferation, migration and stemness. However, mutations in the RUNX1 gene have changed the regulation of these phenotypes and the full spectrum of its implications in breast cancer patients is unknown. In this study therefore, the pattern of RUNX1 mutations in breast cancer patients was examined to understand its fundamental impacts on the disease. The perturbation of RUNX1 and its mutations in breast cancer was elucidated through different studies reported in cBioPortal in the past ten years. From our analyses, the majority of RUNX1 mutations were found in the primary breast cancer, with women constituted most of the mutations, especially on the left side of the breast. Similarly, increased number of mutations was observed in ER-positive breast cancer patients and this was also the case at the early stage of the disease development. The level of RUNX1 mutations also increased gradually as patients got older and the peak was highest in the patients of 60-70 years old. Altogether, these data indicated that the mutated RUNX1 gene contributed to the progression of breast cancer and understanding of its regulatory mechanisms is crucial to therapeutically target this gene in the future.
ELSEVIER GMBH
0344-0338
1618-0631
2024
254

10.1016/j.prp.2023.155076
Pathology

WOS:001164317100001
https://www-webofscience-com.uitm.idm.oclc.org/wos/woscc/full-record/WOS:001164317100001
title Increased RUNX1 mutations in breast cancer disease progression
title_short Increased RUNX1 mutations in breast cancer disease progression
title_full Increased RUNX1 mutations in breast cancer disease progression
title_fullStr Increased RUNX1 mutations in breast cancer disease progression
title_full_unstemmed Increased RUNX1 mutations in breast cancer disease progression
title_sort Increased RUNX1 mutations in breast cancer disease progression
container_title PATHOLOGY RESEARCH AND PRACTICE
language English
format Article
description Despite advances in screening, therapy and surveillance, breast cancer remains threatening to women. Worst, patients suffer from side effects of treatments and cancer cells become resistant. The emergence of RUNX1 in breast cancer has put it in a spotlight due to its roles in the disease progression. It also plays important roles in normal mammary glands such as for cell growth, proliferation, migration and stemness. However, mutations in the RUNX1 gene have changed the regulation of these phenotypes and the full spectrum of its implications in breast cancer patients is unknown. In this study therefore, the pattern of RUNX1 mutations in breast cancer patients was examined to understand its fundamental impacts on the disease. The perturbation of RUNX1 and its mutations in breast cancer was elucidated through different studies reported in cBioPortal in the past ten years. From our analyses, the majority of RUNX1 mutations were found in the primary breast cancer, with women constituted most of the mutations, especially on the left side of the breast. Similarly, increased number of mutations was observed in ER-positive breast cancer patients and this was also the case at the early stage of the disease development. The level of RUNX1 mutations also increased gradually as patients got older and the peak was highest in the patients of 60-70 years old. Altogether, these data indicated that the mutated RUNX1 gene contributed to the progression of breast cancer and understanding of its regulatory mechanisms is crucial to therapeutically target this gene in the future.
publisher ELSEVIER GMBH
issn 0344-0338
1618-0631
publishDate 2024
container_volume 254
container_issue
doi_str_mv 10.1016/j.prp.2023.155076
topic Pathology
topic_facet Pathology
accesstype
id WOS:001164317100001
url https://www-webofscience-com.uitm.idm.oclc.org/wos/woscc/full-record/WOS:001164317100001
record_format wos
collection Web of Science (WoS)
_version_ 1809678794971152384